IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Acquires 11,773 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 11,773 shares of the stock in a transaction dated Tuesday, May 6th. The stock was purchased at an average cost of $1.15 per share, for a total transaction of $13,538.95. Following the acquisition, the insider owned 150,916 shares of the company’s stock, valued at approximately $173,553.40. This represents a 8.46% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Stock Up 2.2%

Shares of IRIDEX stock opened at $0.90 on Friday. The firm has a market cap of $15.78 million, a price-to-earnings ratio of -4.49 and a beta of 0.67. IRIDEX Corporation has a 52-week low of $0.61 and a 52-week high of $1.65. The company’s 50-day simple moving average is $0.73 and its 200-day simple moving average is $0.95.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to the consensus estimate of $13.59 million. Equities research analysts anticipate that IRIDEX Corporation will post -0.12 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, IRIDEX presently has an average rating of “Hold” and a consensus target price of $3.00.

Key Stories Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Institutional Investors Weigh In On IRIDEX

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in IRIDEX during the second quarter worth $29,000. Diversify Advisory Services LLC acquired a new stake in IRIDEX in the second quarter valued at $30,000. Diversify Wealth Management LLC purchased a new position in shares of IRIDEX in the first quarter valued at $35,000. United Capital Financial Advisors LLC purchased a new position in shares of IRIDEX in the second quarter valued at $41,000. Finally, Thompson Davis & CO. Inc. raised its stake in shares of IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 18,944 shares during the last quarter. 20.10% of the stock is currently owned by institutional investors and hedge funds.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.